Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

320 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials.
König D, Schär S, Vuong D, Guckenberger M, Furrer K, Opitz I, Weder W, Rothschild SI, Ochsenbein A, Zippelius A, Addeo A, Mark M, Eboulet EI, Hayoz S, Thierstein S, Betticher DC, Ris HB, Stupp R, Curioni-Fontecedro A, Peters S, Pless M, Früh M. König D, et al. ESMO Open. 2022 Apr;7(2):100455. doi: 10.1016/j.esmoop.2022.100455. Epub 2022 Apr 7. ESMO Open. 2022. PMID: 35398718 Free PMC article.
Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455].
König D, Schär S, Vuong D, Guckenberger M, Furrer K, Opitz I, Weder W, Rothschild SI, Ochsenbein A, Zippelius A, Addeo A, Mark M, Eboulet EI, Hayoz S, Thierstein S, Betticher DC, Ris HB, Stupp R, Curioni-Fontecedro A, Peters S, Pless M, Früh M. König D, et al. ESMO Open. 2022 Jun;7(3):100494. doi: 10.1016/j.esmoop.2022.100494. Epub 2022 Apr 22. ESMO Open. 2022. PMID: 35468561 Free PMC article. No abstract available.
Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14.
König D, Savic Prince S, Hayoz S, Zens P, Berezowska S, Jochum W, Stauffer E, Braunersreuther V, Trachsel B, Thierstein S, Mark M, Schmid S, Curioni-Fontecedro A, Addeo A, Opitz I, Guckenberger M, Früh M, Betticher DC, Ris HB, Stupp R, Rothschild SI, Bubendorf L, Pless M. König D, et al. ESMO Open. 2023 Aug;8(4):101595. doi: 10.1016/j.esmoop.2023.101595. Epub 2023 Jul 11. ESMO Open. 2023. PMID: 37441877 Free PMC article.
Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial.
Froesch P, Mark M, Rothschild SI, Li Q, Godar G, Rusterholz C, Oppliger Leibundgut E, Schmid S, Colombo I, Metaxas Y, König D, Sessa C, Gautschi O, Früh M; Swiss Group for Clinical Cancer Research (SAKK). Froesch P, et al. Among authors: konig d. Lung Cancer. 2021 Jun;156:91-99. doi: 10.1016/j.lungcan.2021.04.002. Epub 2021 Apr 25. Lung Cancer. 2021. PMID: 33933896 Clinical Trial.
Melanoma clonal heterogeneity leads to secondary resistance after adoptive cell therapy with tumor-infiltrating lymphocytes.
König D, Sandholzer M, Uzun S, Zingg A, Ritschard R, Thut H, Glatz K, Kappos EA, Schaefer DJ, Kettelhack C, Passweg JR, Holbro A, Baur K, Medinger M, Buser A, Lardinois D, Jeker LT, Khanna N, Stenner F, Kasenda B, Homicsko K, Matter M, Rodrigues Mantuano N, Zippelius A, Läubli H. König D, et al. Cancer Immunol Res. 2024 Apr 17. doi: 10.1158/2326-6066.CIR-23-0757. Online ahead of print. Cancer Immunol Res. 2024. PMID: 38631025
Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort.
Schmid S, Mauti LA, Friedlaender A, Blum V, Rothschild SI, Bouchaab H, Frösch P, Britschgi C, König D, Wannesson L, Janthur WD, Schär S, Demmer I, Addeo A, Jochum W, Früh M. Schmid S, et al. Among authors: konig d. Cancer Immunol Immunother. 2020 Aug;69(8):1605-1613. doi: 10.1007/s00262-020-02565-0. Epub 2020 Apr 19. Cancer Immunol Immunother. 2020. PMID: 32307579 Free PMC article.
320 results